CD8A and neoplasm: An improved prediction of RFS was accomplished when the ctDNA level was combined with other biomarkers from the tumor microenvironment such as CD8+ T-cells, PD-L1, interferon-gamma (IFN-g) gene expression signature and tumor mutational burden (TMB), but also Breslow level and clinical stage [113].